- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04281758
Comparison of Plasma Caffeine Concentration After Oral Consumption of Caffeinated Beverages With Varied Bioactive Compounds in Healthy Volunteers
This is a Phase 1, double blind, randomized, controlled, cross-over trial.
The primary outcome is to quantify the incremental area-under-the-concentration-curve (iAUC) for plasma caffeine after oral consumption of caffeinated beverages with various bioactive compounds vs. caffeine alone, in 16 healthy volunteers
Secondary outcomes are caffeine concentration at each time point from pre-dose baseline to 3.5 hrs post-dose, peak caffeine concentration (Cmax), time to maximum caffeine concentration (Tmax) and return to baseline concentration (TBR) for plasma caffeine
Other outcomes are ratings of physiological symptoms and mood, assessed using visual analog scales (VAS).
Polyphenol food frequency questionnaire data at screening will be collected as a possible co-variate.
Study Overview
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Minnesota
-
Saint Paul, Minnesota, United States, 55114
- Prism Clinical Research
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy adult male volunteers aged 18 to 55 years.
- Have a BMI of 18 to 29 kg/m2 (inclusive)
- Able to comprehend and willing to sign an Informed Consent Form (ICF).
- Willing to avoid caffeine for ≥48 hrs prior to visits
- Willing to avoid alcohol for ≥24 hrs prior to visits
- Willing to fast 10 hrs prior to visits
- Willing to stick to their usual dietary patterns
- Willing to stick to their usual physical activity level throughout the study
- No participation in any clinical trial within the past 30 days or any PEP protocol within the past 6 months.
Exclusion Criteria:
- Reported history or clinical manifestations of significant metabolic (including type 1 or type 2 diabetes mellitus), hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, urological, neurological, or psychiatric disorders.
- Current or recent history (<30 days prior to Screening) of a clinically significant bacterial, fungal, or mycobacterial infection
- Current clinically significant viral infection
- History of malignancy, with the exception of cured basal cell or squamous cell carcinoma of the skin
- Resting heart rate less than 45 bpm or greater than 100 bpm.
- History of unstable ischemic heart disease or uncontrolled hypertension (blood pressure greater than or equal to 150/90 mm Hg)
- History of stomach or intestinal surgery, except that appendectomy and/or cholecystectomy will be allowed.
- Presence of a malabsorption syndrome possibly affecting drug/Product absorption (e.g., Crohn's disease or chronic pancreatitis).
- Extreme dietary habits, including but not limited to vegetarian diets and intentional consumption of a high fiber diet, gluten-free, low-carb, vegan, ketogenic.
- History of alcoholism or drug addiction within 1 year prior to Screening, or current alcohol or drug use that, in the opinion of the investigator, will interfere with the subject's ability to comply with the dosing schedule and study evaluations.
- Use of any tobacco-containing or nicotine-containing products (including cigarette, pipe, cigar, chewing tobacco, nicotine patch, or nicotine gum and vaping products) within 2 months prior to study entry.
- Use of any prescription or nonprescription drugs (including vitamins, minerals, and phytotherapeutic, herbal, or plant-derived preparations) is prohibited within 7 days prior to the dose of study product, unless deemed acceptable by the Investigator.
- Use of alcohol-containing within 24 hours prior to study entry.
- Use of caffeine containing products 48 hours prior to each dose of study product and during each dosing day.
- Donation of blood in excess of 500 ml within 4 weeks prior to study entry or of plasma within 2 weeks prior to Screening.
- Receipt of blood products within 3 months prior to study entry.
- Subjects who, in the opinion of the investigator, are unable or unlikely to comply with the dosing schedule and study evaluations
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Caffeine beverage (control)
Flavored still beverage with caffeine 100 mg
|
16 oz (473.2 ml)
|
Experimental: Caffeine beverage plus bioactive 1
Flavored still beverage with caffeine 100 mg + quercetin 250 mg
|
16 oz (473.2 ml)
|
Experimental: Caffeine beverage plus bioactive 2
Flavored still beverage with caffeine 100 mg + curcumin 80 mg
|
16 oz (473.2 ml)
|
Experimental: Caffeine beverage plus bioactive 3
Flavored still beverage with caffeine 100 mg + methylliberine 75 mg
|
16 oz (473.2 ml)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incremental area-under-the-concentration-curve (iAUC)
Time Frame: At each of 4 testing days, -30 and 0 min pre-dose, and 15, 30, 45, 60, 90, 120, 150, 180 and 210 minutes post-dose
|
Plasma caffeine level
|
At each of 4 testing days, -30 and 0 min pre-dose, and 15, 30, 45, 60, 90, 120, 150, 180 and 210 minutes post-dose
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Caffeine concentration
Time Frame: At each of 4 testing days, -30 and 0 min pre-dose, and 15, 30, 45, 60, 90, 120, 150, 180 and 210 minutes post-dose
|
Plasma caffeine level
|
At each of 4 testing days, -30 and 0 min pre-dose, and 15, 30, 45, 60, 90, 120, 150, 180 and 210 minutes post-dose
|
Peak caffeine concentration (Cmax)
Time Frame: At each of 4 testing days, -30 and 0 min pre-dose, and 15, 30, 45, 60, 90, 120, 150, 180 and 210 minutes post-dose
|
Plasma caffeine level
|
At each of 4 testing days, -30 and 0 min pre-dose, and 15, 30, 45, 60, 90, 120, 150, 180 and 210 minutes post-dose
|
Time to maximum concentration (Tmax)
Time Frame: At each of 4 testing days, -30 and 0 min pre-dose, and 15, 30, 45, 60, 90, 120, 150, 180 and 210 minutes post-dose
|
Plasma caffeine level
|
At each of 4 testing days, -30 and 0 min pre-dose, and 15, 30, 45, 60, 90, 120, 150, 180 and 210 minutes post-dose
|
Return to baseline concentration (TBR)
Time Frame: At each of 4 testing days, -30 and 0 min pre-dose, and 15, 30, 45, 60, 90, 120, 150, 180 and 210 minutes post-dose
|
Plasma caffeine level
|
At each of 4 testing days, -30 and 0 min pre-dose, and 15, 30, 45, 60, 90, 120, 150, 180 and 210 minutes post-dose
|
Physiological Symptoms
Time Frame: At each of 4 testing days pre-dose, and 60 min, 120 min, and 210 min post-dose
|
VAS scale, 9 terms, each rated on a 100 mm line from "Not at all" to "Extremely'.
Example, not at all irritable is better than extremely irritable.
|
At each of 4 testing days pre-dose, and 60 min, 120 min, and 210 min post-dose
|
Bond-Lader Mood
Time Frame: At each of 4 testing days pre-dose, and 60 min, 120 min, and 210 min post-dose
|
VAS scale,16 terms, each rated on a 100 mm line.
Example, relaxed is better than tense.
|
At each of 4 testing days pre-dose, and 60 min, 120 min, and 210 min post-dose
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Trisha R Shamp, PhD, Prism Clinical Research
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- PEP-1913
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Plasma Caffeine Concentration
-
AstraZenecaCompletedPharmacokinetic Profile | Plasma ConcentrationUnited Kingdom
-
Astellas Pharma IncCompletedHealthy | Plasma Concentration of ASP1941Japan
-
Astellas Pharma IncCompletedHealthy | Plasma Concentration of YM060Japan
-
University of VirginiaThe University of QueenslandCompletedPlasma Concentration of AntibioticsUnited States
-
Astellas Pharma IncCompletedHealthy | Plasma Concentration of YM060Japan
-
Astellas Pharma IncCompletedHealthy | Plasma Concentration Change of QuetiapineJapan
-
Astellas Pharma IncCompletedHealthy Subjects | Plasma Concentration of MirabegronJapan
-
Zhongnan HospitalActive, not recruitingPharmacokinetic | Abiraterone Acetate | Plasma Concentration | Gene Polymorphism | Metabolic AnalysisChina
-
PepsiCo Global R&DCompletedMaximum Observed Plasma Glucose Concentration (Cmax)United States
-
Newcastle UniversityUnknownChange in Fasting Plasma LDL-cholesterol Concentration After the Consumption of QuinoaUnited Kingdom
Clinical Trials on Beverage
-
Unilever R&DCompletedSatiety | AppetiteUnited Kingdom
-
University of CopenhagenCarlsberg Breweries A/SCompletedInsulin Resistance | Alcohol ConsumptionDenmark
-
University of FloridaHeermann Anesthesia FoundationCompleted
-
Old Dominion UniversityRecruitingAnomalies GastrointestinalUnited States
-
Old Dominion UniversityCompletedImpaired ThermoregulationUnited States
-
University of ExeterCompleted
-
Maastricht University Medical CenterUnknownType 2 Diabetes MellitusNetherlands
-
Unilever R&DEurofins OptimedCompleted
-
GlaxoSmithKlineCompleted
-
University of TorontoDairy Management Inc.RecruitingDietary Proteins | Indicator Amino Acid OxidationCanada